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Background: Acute musculoskeletal trauma, including strains, sprains or contusions, occur frequently. Pain
management is a crucial component of treatment. However, there is no convincing evidence which drug is
superior in managing pain in these patients. The aim of the PanAM Study is to compare analgesic efficacy of three
strategies of pain management: paracetamol, diclofenac, or a combination of both in patients with acute
musculoskeletal trauma.
Methods/design: The PanAM Study is a multi-center, double blind randomized controlled trial with non-inferiority
design. Included are adult patients presenting to an academic, urban Emergency Department or to a General
Practice with acute, blunt, traumatic limb injury. In total, 547 patients will be included using a predefined list of
exclusion criteria, to be allocated by randomization to treatment with paracetamol + placebo diclofenac, diclofenac +
placebo paracetamol or paracetamol + diclofenac. The hypothesis is that paracetamol will not be inferior to
treatment with diclofenac, or the combination of both. Primary outcome will be between-group differences in
decrease in pain, measured with Numerical Rating Scales at baseline and at 90 minutes after study drug
administration. Secondary outcomes are Numerical Rating Scales at 30 and 60 minutes and measured frequently
during three consecutive days after discharge; occurrence of adverse effects; patient satisfaction and an analysis of
quality of life and cost-effectiveness. Recruitment started July 2013 and is expected to last a year.
Discussion: With this multi-center randomized clinical trial we will investigate whether treatment with paracetamol
alone is not inferior to diclofenac alone or a combination of both drugs in adult patients with acute musculoskeletal
trauma. The main relevance of the trial is to demonstrate the benefits and risks of three commonly used treatment
regimens for musculoskeletal trauma. Data that lead to the prevention of severe Non-Steroidal Anti-Inflammatory
Drugs-related adverse effects might be gathered.
Trial registration: Dutch Trial Register (http://www.trialregister.nl): NTR3982.
EudraCT database (http://www.clinicaltrialsregister.eu): 201300038111.
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Musculoskeletal trauma has a high incidence. In The
Netherlands, in 2011, 3.3 million injuries were treated med-
ically in a total population of 16.7 million [1]. Taken per
capita, this density is approximately the same in the United
States. In 2006/2007, more than 61.2 million patients with
musculoskeletal injuries were treated annually in the United
States in a total population of 300 million [2]. Most injuries
concern soft tissue, such as strains, sprains and contusions,
also referred to as acute musculoskeletal syndromes [3].
Strains and sprains is a collective term for muscle and liga-
ment injuries without dislocation or fracture. A contusion
is a haemorrhage (usually in the skin) resulting from a dir-
ect trauma. These injuries are often treated in the
Emergency Department or in General Practice. Pain man-
agement in the acute phase is a crucial part of treatment
and can be non-pharmacological (RICE: Rest, Ice, Com-
pression, Elevation) and/or pharmacological [4,5]. The
treating physician prescribes paracetamol (acetaminophen)
or Non-Steroidal Anti-Inflammatory Drugs (NSAID’s), or
patients use these drugs without prescription, as they are
available over the counter. It is unclear, however, whether
NSAID’s have any additional value for the treatment of pain
in patients with an acute musculoskeletal trauma [3]. Be-
cause of supposed efficacy, costs and side effect profile, sev-
eral guidelines mention that paracetamol might be as
appropriate as NSAID’s, however the supporting evidence
is scarce [6,7]. Therefore, there is a need for supportive data
for the effectiveness of paracetamol compared with
NSAID’s in managing pain after acute musculoskeletal
trauma.
Besides the question whether paracetamol is not inferior
to NSAID’s in patients with acute musculoskeletal trauma,
it is important to realize that the use of both drugs can have
detrimental side effects. Paracetamol is an analgesic and
antipyretic, while the exact mechanism of action is not
known. It should be used with attention to dosage, as para-
cetamol overdose is the leading cause of acute liver failure
in the United States and other Western countries [8]. It is
widespread available and frequently, paracetamol is part of
combination preparations. Because many patients have dif-
ficulties identifying prescription and over the counter prod-
ucts containing paracetamol, there is a high risk of
unintentional overdose [9]. NSAID’s are drugs with anal-
gesic and anti-inflammatory properties. They inhibit the en-
zyme cyclooxygenase (COX), which catalyzes the formation
of prostaglandins and thromboxane. In the process of pain,
prostaglandins cause local vasodilation and increased per-
meability of capillaries leading to edema. NSAID’s can have
several potentially severe side effects, especially in older
patients. Even a short course of NSAID’s can cause harm,
such as cardiovascular events [10]. Annually, a considerable
proportion (5.6%) of all unplanned admissions to Dutch
hospitals is related to use of medication [11]. Internationally,these numbers are comparable. Half of these admissions are
potentially preventable and the medications most often in-
volved are, besides anticoagulants, NSAID’s. Reasons for
hospitalization are mainly gastro-intestinal tract problems
and cardiovascular problems. Of the potentially preventable
admissions, 70% of the patients recover completely, however
6.3% die and 9.3% experience a disability after discharge. It
is obvious that, besides the clinical need for the most effect-
ive treatment of pain in patients with an acute musculoskel-
etal trauma, the safety profile of both medications
mentioned is equally important to make a judicious and
evidence-based treatment plan.
The PanAM Study aims to deliver a high level of evi-
dence (A2) answering the clinical question whether pa-
tients with acute musculoskeletal trauma should be
treated with paracetamol, or NSAIDs, or both. The hy-
pothesis is that paracetamol is not inferior to treatment
with diclofenac, or the combination of both. Should
paracetamol appear to be as effective as an NSAID in
treating acute musculoskeletal injuries, use of NSAID’s
could be reduced in this frequent disorder to minimize
the number of NSAID-related adverse effects [12,13].
Methods/design
Ethics
The PanAM Study will be conducted in accordance with
the principles of the Declaration of Helsinki, the Medical
Research Involving Human Subjects Act (WMO) and
‘Good Clinical Practice’ (GCP) guidelines [14,15]. The
protocol was approved by the IRB of the Academic
Medical Center, and the Competent Authority.
Study objectives
The primary objective is to determine which pharma-
cological pain management is best in adult patients
with acute musculoskeletal trauma. The strategies that
are compared are treatment with paracetamol + pla-
cebo diclofenac, diclofenac + placebo paracetamol and
the combination of paracetamol and diclofenac. Sec-
ondary objectives are safety and adverse events, pa-
tient satisfaction and cost-effectiveness.
Study design
The PanAM Study is a multi-center, double-blinded,
randomized, non-inferiority trial.
Setting
Patients will be included in two different settings.
First: 24 hours per day and 7 days per week in
the Emergency Department of a Dutch, urban, uni-
versity hospital with 1032 beds in Amsterdam, The
Netherlands. Annually, approximately 33000 patients
are treated at this Emergency Department. Secondly,
patients will be included in a General Practice in the
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general practitioners work together in this General
Practice with a patient population of approximately
10000 [16].
Study population
All consecutive, adult patients with acute musculo-
skeletal trauma presenting to the Emergency Depart-
ment or to the General Practice will be approached
for inclusion. The allocation ratio in each of the com-
parison groups will be 1:1:1.
The inclusion criteria are:
– adult patient, aged ≥18 years
– non-penetrating limb injury, meaning a painful,
acute strain, sprain or contusion of an extremity
– trauma occurred within 48 hours before
presentation
– pain (mild, moderate and severe) scored with
Numerical Rating Scale (NRS), regardless of amount
of pain.
The exclusion criteria are:
– previous treatment with analgesia for the same
injury
– self inflicted injury (“auto-mutilation”)
– presence of wound, joint dislocation or more than
one injury
– presence of a fracture. An X-ray is done when
estimated necessary by the treating pysician in order
to exclude a fracture.
– daily use of paracetamol and/or NSAID’s and/or
other analgesia within two weeks before
presentation
– patients with chronic pain
– previous adverse reaction or known allergy to
paracetamol, NSAID’s or omeprazole
– a known pregnancy
– previous gastro-intestinal hemorrhage or perforation
after NSAID use
– active or recurrent peptic ulceration or peptic
bleeding (2 or more evident episodes)
– previous exacerbation of asthma after use of
NSAID’s or acetylsalicylic acid
– severe cardiac failure
– liver cirrhosis
– severe renal insufficiency (a known Glomerular
Filtration Rate <30 mL/min)
– bone marrow depression or blood dyscrasia
(active or in past medical history)
– combined use of angiotensin converting enzyme
inhibitors (or angiotensin receptor blockers) AND
diuretics [17]– physical, visual or cognitive impairment or non-
Dutch language speaking (unable to use NRS, pain
diary or EQ5D questionnaire)
All patients are treated in the Emergency Department
or in General Practice and will not be admitted for sur-
gery subsequently.
The study consists of three different phases
Phase one
A patient presenting to the Emergency Department or
the General Practice with an acute musculoskeletal
trauma will be screened whether eligible for inclusion in
the study. In the General Practice, this will be done by
the physician and in the Emergency Department by a re-
search assistant. Both have received a one-hour training
of the research staff about all aspects of the study. If the
patient is eligible, informed consent is obtained,
randomization takes place and the patient is allocated to
one of the three treatments. Figure 1 shows the study
flow chart of phase one. Baseline characteristics are
noted and pain in rest and with movement of the ex-
tremity is scored, using the NRS (T0). Patients verbally
rate their pain intensity from 0 to 10; 0 being no pain
and 10 being the worst possible pain. The patient re-
ceives two boxes of blinded study drugs. Box one con-
tains 24 tablets paracetamol 500 mg or paracetamol-like
placebo. Box two contains 9 tablets diclofenac 50 mg or
diclofenac-like placebo. At T0, the patient takes two tab-
lets from box one and one tablet from box two. All
study drugs are taken orally. The combination of
paracetamol-like placebo and diclofenac-like placebo is
considered unethical (to fully withhold analgesia in pa-
tients with painful injuries). The possible treatment
strategies with study drugs are:
1. paracetamol 1000 mg qid (quater in die = four times
daily) + diclofenac-like placebo tds (ter die sumendus =
three times daily)
2. paracetamol 1000 mg qid + diclofenac 50 mg tds
3. paracetamol-like placebo qid + diclofenac 50 mg tds
Besides these drugs, all patients take the proton pump
inhibitor omeprazole 20 mg qd (quaque die = once daily)
for prevention of gastric internal bleeding during three
days. Pain is re-evaluated at 30, 60 and 90 minutes (T30,
T60 and T90). At T90, patient satisfaction is scored
using a 5-point Likert scale with two questions. The oc-
currence of adverse events is recorded and the patient is
discharged home. Phase one ends here.
Phase two
Figure 2 shows the study flow chart of phase two and
phase three. After discharge, the patient takes home the
Patients with painful 
isolated limb injuries
presenting in the ED / 
general practice






Paracetamol 1000 mg + 
Diclofenac placebo*
T0
Measure pain NRS 
Paracetamol placebo + 
Diclofenac 50 mg*
T0
Measure pain NRS 
Paracetamol 1000 mg + 
Diclofenac 50 mg*
T30
Measure pain NRS / 
Adverse events
T30
Measure pain NRS /
Adverse events
T30 
Measure pain NRS /
Adverse events
T60
Measure pain NRS / 
Adverse events
T60 
Measure pain NRS / 
Adverse events
T60
Measure pain NRS / 
Adverse events
Discharge home with 
study medication + diary
Discharge home with 
study medication + diary
Discharge home with 
study medication + diary
T90
Measure pain NRS / 
Adverse events / Patient 
satisfaction Likert Scale
T90
Measure pain NRS / 
Adverse events / Patient 
satisfaction Likert Scale
T90
Measure pain NRS / 
Adverse events / Patient 
satisfaction Likert Scale
* All patients will take Omeprazol 20 mg non-blinded
Figure 1 Flow chart phase one of the study. The flow chart depicts how patients are included in the study at the time of presentation in the
Emergency Department or in general practice. T0 is the time of baseline measurement and administration of study drugs. T30 is 30 minutes after
study drug administration, whereas T60 and T90 are 60 and 90 minutes respectively after study drug administration.
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pain diary patients can score their pain each day three
times a day during three days, in rest and with daily ac-
tivities. During these three days the patient uses the
same, blinded study drugs as mentioned in phase one.
Patients can record adverse effects in the pain diary inpredefined fields as well as in open fields. The EQ5D
questionnaire is filled in daily and patient satisfaction
using a 5-point Likert scale is recorded after three days
[18]. In case additional analgesia is required, the patient
can get a prescription of the treating physician. The
physician will prescribe tramadol or another opioid, as it
Discharge from ED or 
general practice with 
study medication and 
pain diary
During 3 days:
Paracetamol 1000 mg qid 
+ Diclofenac placebo tds*
Measure pain in rest and 
activity tds / Adverse 
events
EQ5D questionnaire qd
Patient satisfaction 3rd day
During 3 days:
Paracetamol placebo qid 
+ Diclofenac 50 mg tds*
Measure pain in rest and 
activitiy tds / Adverse 
events
EQ5D questionnaire qd
Patient satisfaction 3rd day
During 3 days:
Paracetamol 1000 mg qid 
+ Diclofenac 50 mg tds*
Measure pain in rest and 
activity tds / Adverse 
events 
EQ5D questionnaire qd
Patient satisfaction 3rd day
Follow-up 1-3 days by 
telephone
Follow-up 1-3 days by 
telephone
Follow-up 1-3 days by 
telephone
Pain diary sent back to 
research staff
Pain diary sent back to 
research staff
Pain diary sent back to 
research staff
Follow-up one month after 
discharge by telephone 
end of study
Follow-up one month after 
discharge by telephone 
end of study
Follow-up one month after 
discharge by telephone 
end of study
Figure 2 Flow chart phase two and three of the study. The flow chart depicts what study drugs patients take during three consecutive days,
which parameters they record in the pain diary and when research staff contacts the patients. It shows the end of the study after the follow-up
by phone after one month.
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already using. Use of non-pharmacologic treatment
(such as icepacks, bandages, crutches, etc) is docu-
mented. The patient sends the pain diary to the Emer-
gency Department by post using the envelope.Phase three
Phase three starts after the three days use of the study
drugs and ends at 30 days after inclusion with a final
follow-up by phone. The EQ5D health questionnaire is
recorded, as well as the following parameters: use of
additional pain medication, (late) occurrence of adverse
events of study drugs, total days of leave from work and
interventions needed. These interventions include phys-
ician visits, hospital admissions or surgery, care of a fam-
ily caregiver, nursing at home, (paid) help needed in the
household or temporary support in another way. Theend of phase three is the end of the study for the
participant.
Endpoints
Primary outcome is between-group difference in de-
crease in pain (measured with NRS) at baseline and at
90 minutes after study drug administration in phase one
of the study. Pain will be measured in rest and with
movement of the extremity.
Secondary study parameters are
– NRS at 30 and 60 minutes and pain measured
during three consecutive days after discharge, in rest
and with usual daily activity (walking, bathing, going
to the toilet) three times daily.
– proportional changes in pain; <33% or >33%
decrease and Number Needed to Treat (NNT) to
achieve 33% decrease in NRS.
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– patient satisfaction with pain relief in phase one and
phase two, using a 5-point Likert scale with two
questions.
– need for additional pain medication in all phases and
use of non-pharmacologic co-interventions.
– analysis of quality of life and economic evaluation
– baseline parameters: age, sex, medical history and
medication use, date of injury and date of visit,
mechanism of trauma, type and site of injury and
use of non-pharmacological co-interventions.
Randomization
After confirmation of eligibility for the trial and obtaining
written informed consent, the patient is allocated to a
blinded study drug treatment using a randomization list.
The randomization list was created in advance by the Clin-
ical Research Unit for statistical and epidemiological sup-
port in conjunction with the trial pharmacy. The trial
pharmacy packed the study drugs in identical, blinded
packages and labeled the packages with the randomization
numbers. A fixed block size of 9 is used. Patients are strati-
fied in subgroups younger and older than 60 years. After in-
cluding a patient in the study, an online randomization
module is used to obtain the randomization number
(ALEA Software for Randomization in Clinical Trials, ver-
sion 2.2, Copyright 2004 NKIAVL Amsterdam, NL). The
study drug package labeled with this randomization num-
ber is picked up by the research assistant and the study
starts for the participant. Patients, care providers and asses-
sors of outcomes are all blinded for the assigned study
drug.
Study drugs
The study drugs are manufactured according to Good
Manufacturing Guidelines (GMP) Annex 13. Manage-
ment of study drugs is performed according to Dutch
national law and Good Clinical Practice (GCP). Para-
cetamol and placebo paracetamol as well as diclofenac
and placebo diclofenac have similar appearances.
Sample size calculation and statistical analysis
The primary outcome (difference in NRS between groups)
is expected to be distributed normally. In a pilot study we
found a standard deviation of decrease in NRS score of
2.06. The equivalence limit is chosen at 0.75 to be certain
that the value is well below the clinical relevant difference
between NRS measurements of 1.3. This 1.3 difference in
NRS is chosen, based on prior work by several investigators
that identified the minimally clinically significant difference
in pain as 1.3 units on an NRS [19,20]. As we want to assess
non-inferiority two times (once between the paracetamol
and diclofenac group and once between the paracetamol
and combination group), we use a Bonferroni adjustmentof the significance level to protect against type I error.
Using this data, a one sided t-test with a significance level
of 0.0125, an equivalence limit of 0.75 and an expected dif-
ference of 0 between two groups, will have 85% power to
reject the null hypothesis that ‘paracetamol only’ is inferior
to one of the other groups when the sample size in each
group is 164. With three groups and taking into account an
anticipated loss to follow-up of 10% we will need 547 pa-
tients totally. It is expected that this number of study sub-
jects is reached within a year. In case the null-hypothesis,
that paracetamol is inferior to the other two treatment
strategies, will be accepted, a secondary analysis will be
done. This secondary analysis will investigate superiority of
diclofenac or the combination of both versus paracetamol.
It can be undertaken with a one-sided T-test, a significance
level of 0.0125 (Bonferroni adjustment) and 90% power to
detect a clinical significant between group difference of 1.3
in NRS [21]. In each group, 64 patients are needed for this
analysis, meaning that enough patients will already be in-
cluded. Continuous data conforming to a normal distribu-
tion will be analyzed using one-way analysis of variance
and Kruskal-Wallis test is used for continuous data without
a normal distribution. Unpaired ordinal data will be ana-
lyzed using Chi Square test or the Fisher exact test. Paired
ordinal data will be analyzed using generalized estimating
equations (GEE models). A planned subgroup analysis will
be done in patients older than 60 years, as these patients
are more likely to develop adverse effects when using
NSAID’s. Data will be analyzed using SPSS version 19.0
SPSS Inc., Chicago, IL.
Economic evaluation
Economic evaluation will include costs-effectiveness
analysis (primary outcome costs per unit decrease in
pain) and cost-utility analysis (costs per quality adjusted
life year (QALY)) from a social perspective with a time
horizon to 1 month after discharge by follow-up by
phone to measure relevant effects and costs. For analysis
of quality of life, health outcomes will be assessed using
Euroqol – EQ5D questionnaire during the first three
days and after one month by telephone. Previous re-
search has determined the utility of each observed health
score profile on the EQ-5D based on the time trade-off
elicitation technique during interviews with adults from
the Dutch general population [22]. QALYs will be calcu-
lated by the product sum of the utility of each health
state and the times in between the actual observations of
those health states and the previous ones.
Direct and indirect medical and non-medical costs will
be included in the economic evaluation, as well as health-
related costs for patients and family and costs of loss of
productivity. Medical costs will include the costs of initial
evaluation of the patient, as well as follow-up needed and
interventions needed (with all diagnostic and therapeutic
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drugs occur. Unit costing will be based on available national
costing guidelines for health care research. Direct and indir-
ect non-medical costs of, respectively, out-of-pocket ex-
penses and production loss during the first month after
sustaining the injury will be estimated. Indirect costs of
production loss will be calculated with the friction cost
method, based on the Dutch situation. Costs will be esti-
mated for the base year 2013; price-indexing will be applied
for unit costs originating from different calendar years.
Monitoring
An Internal Medicine Physician with a specialization in
Clinical Pharmacology and Acute Internal Medicine,
who is not related to the study, is appointed as a safety
monitor. The safety monitor is blinded. Adverse events
are presented to the safety monitor and findings will be
reported in a regular format to the principal investigator
and the coordinating investigators. Monitoring visits for
GCP compliance will be scheduled once a year at each
study site and the following are included in the monitor-
ing plan: inclusion speed and drop out percentage; pres-
ence and completeness of the research files; informed
consents; in- and exclusion criteria; Source Data Verifi-
cation; occurrence of Serious Adverse Events (SAE’s)
and verification of the procedures following this; patient
instructions and instructions for execution of study pro-
cedures and management of study medication according
to GCP and Dutch national law.
As the study is estimated to be a study of low risk (ap-
proved drugs in regular doses used for a short period in
a population that uses the drugs every day in current
clinical practice), there is no need to install a formal
Data Safety Monitoring Board (DSMB).
Discussion
Acute musculoskeletal trauma occurs frequently in The
Netherlands as well as in other Western Countries [1,2].
There is no conclusive evidence about pharmacologic
treatment of these injuries and whether paracetamol is
as effective as an NSAID. A systematic review from 2010
analyzed two Randomized Controlled Trials (RCT’s)
comparing paracetamol to NSAID’s in patients with
musculoskeletal disorders [3]. The first was a trial from
Hong Kong comparing three days of oral paracetamol
4000 mg, indometacin 75 mg, diclofenac 75 mg and
paracetamol 4000 mg + diclofenac 75 mg in 300 patients
with musculoskeletal injuries of back, neck and extrem-
ities showing no significant difference in pain relief in
the acute phase and three consecutive days [23]. It is
questionable whether these results can be extrapolated;
diclofenac was dosed lower than in daily practice in The
Netherlands and other Western countries. The authors
concluded that other studies would be required toaddress this issue. In the second RCT 260 patients with
ankle sprains were treated with paracetamol 3900 mg or
ibuprofen 1200 mg daily [24]. There was no significant
difference in pain reduction. Two other RCT’s from
2007 and 2011 found no significant difference in de-
crease in Visual Analogue Scale (VAS) in 100 and 90 pa-
tients, treated for ankle sprains five and ten days
respectively with diclofenac 150 mg or paracetamol
1500 mg daily [25,26]. It is questionable whether these
results can be extrapolated, as the daily dose paraceta-
mol used in The Netherlands is much higher. Direct
comparison studies between paracetamol and NSAID’s
in other clinical problems than musculoskeletal trauma
show varying results [27]. NSAID’s seem more effective
in dental and menstrual pain, but both drugs provide
equivalent analgesia in orthopedic surgery and tension
headache.
The current study aims to provide evidence whether
paracetamol is or is not inferior to diclofenac or a com-
bination of paracetamol and diclofenac in adult patients
with acute musculoskeletal trauma. Diclofenac 50 mg
tds was chosen, because this drug in this dose is com-
mon practice in the Netherlands and frequently used in
patients with acute musculoskeletal trauma. The com-
bination of paracetamol and diclofenac is also often pre-
scribed. In literature, this drug combination is frequently
used in treating patients with postoperative pain [28,29].
The reason for combining two analgesic drugs with dif-
ferent pharmacological modes of action is that they
might work supra-additively; their analgesic effects
might enhance each other. In daily clinical practice, the
superiority of the combination of paracetamol and
NSAID’s has not been proven so far [30]. The authors of
a systematic review from 2010 concluded that the com-
bination of paracetamol and diclofenac might give better
results with respect to pain relief [31]. However, this re-
view included studies with differences in methodology
that can significantly influence the results in pain score.
At first, the review included studies in patients with pain
in the peri-operative setting, where analgesic drugs are
frequently administered before patients experience pain.
Secondly, in some of the studies included in this review
drugs were administered rectally instead of orally and
the absorption and the rate of absorption differ between
rectal and oral use. Finally, in several studies included,
paracetamol and diclofenac were used in different dos-
ages. The results of this systematic review therefore can-
not be used in the daily clinical, non-operative setting,
from which the patients in the PanAM Study are
selected.
The non-inferiority design, with the null hypothesis that
there is a significant negative difference in NRS, is chosen
as study design, as this is thought to harvest study results
that will be the most relevant to daily clinical practice.
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nac or the combination of paracetamol and diclofenac (i.e.
the alternative hypothesis is accepted), sufficient evidence is
supplied that NSAID’s should not be prescribed to patients
with acute musculoskeletal trauma. This will hopefully lead
to a decrease in NSAID-related adverse effects. When the
study results will be such that the null hypothesis will be ac-
cepted, a secondary analysis will take place to investigate
whether diclofenac or the combination of both drugs is sta-
tistically superior to the use of paracetamol.
In the PanAM Study, patients are included in an
Emergency Department and in a General Practice. By
selecting patients in these different centers, the results
of the PanAM Study will be easily generalized to daily
clinical practice, as patients with acute musculoskeletal
trauma present to these different centers daily.
The occurrence of adverse drug effects could have
been chosen as primary endpoint of the study, as it
would be expected that NSAID’s would have more ad-
verse effects than paracetamol, used in therapeutic dos-
ages. Instead, between- group difference in decrease in
NRS is chosen as primary outcome. It is unknown which
of three studied treatment strategies is the most effective
in patients with acute musculoskeletal trauma. Having
used the occurrence of adverse effects as primary end-
point would have resulted in a very large population
needed for the study. Proportional changes in pain are
used as secondary endpoints. A decrease in NRS of more
or less then 33% and the NNT to achieve 33% decrease
in NRS are used. In 2009, Chang mentioned that there is
no consensus about the best way to measure efficacy of
different pain regimens [32]. By adding these secondary
endpoints, we would like to determine whether the find-
ings of the primary outcome will be concordant with
these secondary outcomes.
In the PanAM Study, all subjects receive omeprazole for
gastric protection. The bias of safety results that will inevit-
ably occur is not relevant to our results, as we primarily
aim to measure effectiveness. We realize that the adverse
effects of diclofenac measured in this trial are underesti-
mated. This strategy is the only ethical way to include eld-
erly patients in this study, as the Dutch national guideline
“Use of NSAIDs and prevention of peptic injury” advises
prescribing proton pump inhibitors when NSAID’s are used
in all patients older than 60 years [33]. The guideline also
states that a proton pump inhibitor should be administered
when prescribing NSAID’s in patients with a past history of
peptic ulcer or untreated H. pylori infection; use of anti
coagulants; severe rheumatoid arthritis; heart failure or
diabetes; use of corticosteroids or Selective Serotonine Re-
Uptake Inhibitors (SSRI’s). As we aim to treat all partici-
pants exactly the same way to prevent co‐intervention bias,
we choose to administer omeprazole to all patients in this
study. The alternative would be to exclude all patients withhigher risk of NSAID-related GI-events, however, as we are
highly interested in the group of elderly patients in a sub-
group analysis, this is not feasible.
The PanAM trial will focus on the question which
pharmacologic pain treatment is best in patients with
acute musculoskeletal trauma and will highlight the sub-
group of patients older then 60 years. This group seems
vulnerable when using NSAID’s as the occurrence of ad-
verse events seems to increase with increasing age.
Conclusion
The PanAM Study is a multi-center, double blind, non-
inferiority trial that aims to answer the question whether
paracetamol is not inferior to diclofenac or paracetamol +
diclofenac in the treatment of pain sustained from acute
musculoskeletal trauma.
Prospective
Inclusion at the Emergency Department started July 2013.
Inclusion at the General Practice is planned to start Octo-
ber 2013. The study is expected to last for one year.
Abbreviations
CA: Competent authority; CCMO: Central Committee on Research Involving
Human Subjects (in Dutch: Centrale Commissie Mensgebonden Onderzoek);
COX: CycloOxygenase; DSMB: Data Safety Monitoring Board;
EudraCT: European Union Drug Regulating Authorities Clinical Trials;
GCP: Good clinical practice; GMP: Good manufacturing practice;
NRS: Numerical rating scale; NSAID’s: Non-steroidal anti-inflammatory drugs;
QALY: Quality adjusted life year; qd: quaque die = once daily; qid: quater in
die = four times daily; RCT: Randomized controlled trial; SAE: Serious adverse
event; tds: ter die sumendus = three times daily; VAS: Visual analog scale;
WMO: Medical Research Involving Human Subjects Act (in Dutch: Wet
Medisch-Wetenschappelijk Onderzoek met Mensen).
Competing interests
ML Ridderikhof, MD, is a PhD Student at the departments of Anesthesiology
and Traumatology, employed by the Academic Medical Center as a staff
member of the department of Emergency Medicine. As a researcher, he is
supported by a grant from ZonMW, the Netherlands organization for health
research and development with grant number: 836011015. All authors
declare that they do not have any competing interests.
Authors' contributions
MR designed and coordinates the study, created the paper as well as the
electronic case report forms and drafted the manuscript. MR was funded
partially from the ZonMW grant. PL, AH, WG, JL, MK, MD, MH and CG helped
designing and coordinating the study. AH helps coordinating the study in
the General Practice. WG and MD helped with the statistical and economic
analysis. MK is responsible for coordination and distribution of study
medication in both study sites. All authors revised and corrected earlier
versions of the manuscript critically. All authors read and approved the final
version of this manuscript.
Acknowledgements
We thank Rob Boxma and Corine Mooldijk for graphically designing and
printing patient information and pain diaries on behalf of ‘Tafel 32’ graphic
office. We thank Miranda Mul from the Clinical Research Unit for creating the
randomization list and database support. We thank Gerben Rienk Visser and
Annelies Rotte for training and support in using electronic case report forms
in OpenClinica and Jolanda Strubel for finalizing and continuously
supporting in the use of OpenClinica. We thank Dianne Chantalou, Bo
Geraedts, Laura Haasnoot, Sharla Hagenaars, Meike Hulshof, Roswitha Leijen,
Shailin Balgobind, Lidija Rakic, Madeleine Tromp, Jip van de Berg, Nicole van
der Werff, Patricia van Tongeren and Lisette Willers for acquisition of data.
Ridderikhof et al. BMC Emergency Medicine 2013, 13:19 Page 9 of 9
http://www.biomedcentral.com/1471-227X/13/19The authors obtained permission to acknowledge from all those mentioned
in this section.Funding
ZonMW (the Netherlands organisation for health research and development):
grant number 836011015.
Author details
1Department of Emergency Medicine; Academic Medical Center, PO Box
22660, 1100 DD, Amsterdam, The Netherlands. 2Department of
Anaesthesiology; Academic Medical Center, PO Box 22660, 1100 DD,
Amsterdam, The Netherlands. 3Trauma Unit Department of Surgery;
Academic Medical Center, PO Box 22660, 1100 DD, Amsterdam, The
Netherlands. 4General Practice “Health Care Center Gein”, Wisseloordplein 50,
1106 MH, Amsterdam, The Netherlands. 5Department of Pharmacy; Academic
Medical Center, PO Box 22660, 1100 DD, Amsterdam, The Netherlands.
6Clinical Research Unit; Academic Medical Center, PO Box 22660, 1100 DD,
Amsterdam, The Netherlands.
Received: 10 September 2013 Accepted: 14 November 2013
Published: 20 November 2013References
1. Den Hertog P, Stam C, Valkenberg H, Bloemhoff A, Panneman M, Klein Wolt
K: Letsel in Nederland. In Letsels en letselpreventie. Amsterdam: VeiligheidNL;
2013:14. In Dutch.
2. United States Bone and Joint Initiative: The Burden of Musculoskeletal
Diseases in the United States. 2nd edition. Rosemont, IL: American Academy
of Orthopaedic Surgeons; 2011.
3. Gøtsche PC: NSAIDs. Clin Evid 2010, 06:1108.
4. Harvey R: Musculoskeletal disorders: Managing sprains and strains.
Pharma J 1997, 259:292–295.
5. McGriff-Lee N: Management of acute soft tissue injuries. J Pharm Pract
2003, 16:51–58.
6. Berben SA, Kemps HH, van Grunsven PM, Mintjes-de Groot JA, van Dongen
RT, Schoonhoven L: Guideline ’Pain management for trauma patients in
the chain of emergency care. Ned Tijdschr Geneeskd 2011, 155:A3100.
Article in Dutch.
7. National Institute for Health and Care Excellence (NICE): Clinical Knowledge
Summaries (CKS). Sprains and Strains [http://cks.nice.org.uk/sprains-and-
strains#!supportingevidence1:2] [Accessed May 24th 2013].
8. Khashab M, Tector AJ, Kwo PY: Epidemiology of acute liver failure.
Curr Gastroenterol Rep 2007, 9:66–73.
9. Boudreau DM, Wirtz H, Von Korff M, Catz SL, St.John J, Stang PE: A survey
of adult awareness and use of medicine containing acetaminophen.
Pharmacoepidem Dr S 2013, 22:229–240.
10. Schjerning Olsen A-M, Fosbøl EL, Lindhardsen J, Folke F, Charlot M,
Selmer C, Lamberts M, et al: Duration of treatment with nonsteroidal
anti-inflammatory drugs and impact on risk of death and recurrent
myocardial infarction in patients with prior myocardial infarction: a
nationwide cohort study. Circulation 2011, 123:2226–2235.
11. Leendertse AJ, Egberts ACG, Stoker LJ, Van den Bemt PMLA, for the HARM
Study Group: Frequency of and Risk Factors for Preventable Medication-
Related Hospital Admissions in the Netherlands. Arch Intern Med 2008,
168(17):1890–1896.
12. Williams K: Evidence on NSAID use in soft tissue injuries. Nurs Times 2012,
108:12–14.
13. Braund R: Should NSAIDs be routinely used in the treatment of sprains
and strains? PJ 2006, 276:655–656.
14. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving
Human Subjects. [http://www.wma.net/en/30publications/10policies/b3/]
webcite 013.
15. The International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use / Good Clinical Practice (ICH/
GCP); 2013. http://ichgcp.net.
16. Foundation Healthcare Centers Amsterdam South East: Annual Report 2009.
[http://gazo.praktijkinfo.nl/nieuws/35/gazo-jaarverslag-2012/] [Document in
Dutch].
17. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S: Concurrent use of diuretics,
angiotensin converting enzyme inhibitors, and angiotensin receptorblockers with non-steroidal anti-inflammatory drugs and risk of acute
kidney injury: nested case-control study. BMJ 2013, 346:e8525.
18. Brooks R: EuroQol: the current state of play. Health Policy 1996,
37(1):53–72.
19. Bijur PE, Latimer CT, Gallagher EJ: Validation of a verbally administered
numerical rating scale of acute pain for use in the emergency
department. Acad Emerg Med 2003, 10:390–392.
20. Kendrick DB, Strout TD: The minimum clinically significant difference in
patient-assigned numeric scores for pain. Am J Emerg Med 2005,
23:828–832.
21. Sackett DL: Superiority trials, non-inferiority trials, and prisoners of the
2-sided null hypothesis. Evid Based Med 2004, 9:38–39.
22. Lamers LM, Stalmeier PFM, McDonnell J, Krabbe PFM, Van Busschbach JJ:
Measuring quality of life in economic evaluations: the Dutch EQ-5D-
tariff. Ned Tijdschr Geneeskd 2005, 149:1574–1578.
23. Woo WWK, Man S-Y, Lam PKW, et al: Randomized double-blind trial
comparing oral paracetamol and oral nonsteroidal antiinflammatory
drugs for treating pain after musculoskeletal injury. Ann Emerg Med 2005,
46:352–361.
24. Dalton JD, Schweine JE: Randomized controlled noninferiority trial to
compare extended release acetaminophen and ibuprofen for the
treatment of ankle sprains. Ann Emerg Med 2006, 48:615–623.
25. Kayali C, Agus H, Surer L, Turgut A: The efficacy of paracetamol in the
treatment of ankle sprains in comparison with diclofenac sodium.
Saudi Med J 2007, 12:1836–1839.
26. Lyrtzis C, Natsis K, Papadopoulos C, Noussios G, Papathanasiou E: Efficacy of
Paracetamol Versus Diclofenac for Grade II Ankle Sprains. Foot Ankle Int
2011, 32:571–575.
27. Sachs CJ: Oral analgesics for acute nonspecific pain. Am Fam Physician
2005, 71:913–918.
28. Merry A, Power I: Perioperative NSAIDs: towards greater safety. Pain Rev
1995, 2:268–291.
29. Rømsing J, Møiniche S, Dahl JB: Rectal and parenteral paracetamol, and
paracetamol in combination with NSAID’s, for postoperative analgesia.
Br J Anaesth 2002, 88:215–226.
30. Ong CKS, Lirk P, Tan CH, Seymour RA: An evidence-based update on
nonsteroidal anti-inflammatory drugs. Clin Med Res 2007, 5:19–34.
31. Ong CKS, Seymour RA, Lirk P, Merry AF: Combining paracetamol
(acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative
systematic review of analgesic efficacy for acute postoperative pain.
Anesth Analg 2010, 110:1170–1179.
32. Chang AK, Bijur PE, Baccelieri A, Gallagher EJ: Efficacy and safety profile of
a single dose of hydromorphone compared with morphine in older
adults with acute, severe pain: a prospective, randomized, double-blind
clinical trial. Am J Geriatr Pharmacother 2009, 7:1–10.
33. Moens HJ, van Croonenborg JJ, Al MJ, van den Bemt PM, Lourens J,
Numans ME, Working Group, Kwaliteitsinstituut voor de Gezondheidszorg
CBO: Guideline ’NSAID use and the prevention of gastric damage.
Ned Tijdschr Geneeskd 2004, 148:604–608. Article in Dutch.
doi:10.1186/1471-227X-13-19
Cite this article as: Ridderikhof et al.: The PanAM study: a multi-center,
double-blinded, randomized, non-inferiority study of paracetamol
versus non-steroidal anti-inflammatory drugs in treating acute
musculoskeletal trauma. BMC Emergency Medicine 2013 13:19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
